NCT05171647 2026-03-06
SUNMO
Hoffmann-La Roche
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT03274492 2026-02-06
POLARIX
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04323956 2026-02-02
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
Phase 1 Active not recruiting
NCT05954910 2026-02-02
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Active not recruiting
NCT03533283 2026-01-06
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04594798 2025-12-17
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
University of Rochester
Phase 2 Active not recruiting
NCT05410418 2025-12-15
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04479267 2025-09-29
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Active not recruiting
NCT04665765 2025-09-03
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05498220 2025-09-02
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05798156 2025-05-02
R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT03671018 2024-11-29
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04914741 2024-08-12
COALITION
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting